Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-649-3530
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.56 million
Profitability
Miscellaneous
Employees122
OptionableOptionable
Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions
What is Coherus Biosciences' stock symbol?
Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus Biosciences' earnings last quarter?
Coherus Biosciences Inc (NASDAQ:CHRS) released its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.08. View Coherus Biosciences' Earnings History.
When is Coherus Biosciences' next earnings date?
What price target have analysts set for CHRS?
4 Wall Street analysts have issued twelve-month price objectives for Coherus Biosciences' shares. Their forecasts range from $25.00 to $45.00. On average, they anticipate Coherus Biosciences' stock price to reach $30.75 in the next twelve months. This suggests a possible upside of 162.4% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.
What is the consensus analysts' recommendation for Coherus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.
Has Coherus Biosciences been receiving favorable news coverage?
News stories about CHRS stock have been trending very positive on Monday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Coherus Biosciences earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Coherus Biosciences' key competitors?
Some companies that are related to Coherus Biosciences include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA).
Who are Coherus Biosciences' key executives?
Coherus Biosciences' management team includes the folowing people:
- Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 63)
- Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 52)
- Dr. Peter K. Watler, Chief Technical Officer (Age 56)
- Dr. Barbara K. Finck, Chief Medical Officer (Age 71)
- Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 66)
Who are Coherus Biosciences' major shareholders?
Coherus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boston Advisors LLC (0.05%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Institutional Ownership Trends for Coherus Biosciences.
Which major investors are selling Coherus Biosciences stock?
CHRS stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Coherus Biosciences company stock in the last year include Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Insider Buying and Selling for Coherus Biosciences.
Which major investors are buying Coherus Biosciences stock?
How do I buy shares of Coherus Biosciences?
Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus Biosciences' stock price today?
One share of CHRS stock can currently be purchased for approximately $11.72.
How big of a company is Coherus Biosciences?
Coherus Biosciences has a market capitalization of $797.25 million and generates $1.56 million in revenue each year. The biotechnology company earns $-238,170,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Coherus Biosciences employs 122 workers across the globe.
What is Coherus Biosciences' official website?
How can I contact Coherus Biosciences?
Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]
MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
